Trial Profile

A multicenter, open-label, randomized, study to compare the efficacy and safety of indinavir 800 mg b.i.d. [twice daily] plus ritonavir 100 mg b.i.d. plus two NRTIs [nucleoside reverse transcriptase inhibitor] vs. nelfinavir 1250 mg b.i.d. plus two NRTIs in HIV-1 seropositive patients who have failed or are intolerant to an NNRTI [non-nucleoside reverse transcriptase inhibitor] containing regimen

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Indinavir (Primary) ; Nelfinavir; Nucleoside reverse transcriptase inhibitors; Ritonavir
Indications HIV-1 infections
Focus Therapeutic Use
Sponsors Merck & Co; Merck Sharp & Dohme

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com